Minocycline topical- BioPharmX Corporation

Drug Profile

Minocycline topical- BioPharmX Corporation

Alternative Names: BPX-01; BPX-01 1% minocycline - BioPharmX Corporation

Latest Information Update: 17 Jul 2017

Price : $50

At a glance

  • Originator BioPharmX Corporation
  • Class Amides; Antibacterials; Dimethylamines; Neuroprotectants; Small molecules; Tetracyclines
  • Mechanism of Action Protein 30S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Acne vulgaris; Rosacea

Most Recent Events

  • 13 Jul 2017 Additional adverse events data from a phase IIb trial in Acne Vulgaris released by BioPharmX Corporation
  • 01 Jun 2017 Comprehensive efficacy, safety and pharmacokinetic data from a phase IIb trial Acne vulgaris released by BioPharmX
  • 04 May 2017 Interim efficacy and adverse events data from a phase IIb trial in Acne vulgaris released by BioPharmX
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top